In what will without question be a crushing blow to the solar industry, the European Union is ready to punish Chinese solar imports with a huge tariff imposed on them of an average of 47 percent, for the majority of photovoltaic panels. Most people are scratching their heads over this, as it'll harm the largest solar farms in the EU, and only benefit a small group of solar manufacturers. Many feel if the June 6 deadline is adhered to, it will crush the solar industry, and not only in China.
This is the result of the Chinese dominating a market once controlled by European companies. Fast growth by Chinese manufacturers has resulted in a glut, which has shrunk margins, pushing a number of companies into bankruptcy.
What is strange is if the EU was going to take action, it should have been long ago, not when the damage has already been done. It's more a representation of being sore losers than attempting to level the playing field, as European representatives assert.
Best Japanese Companies To Watch For 2015: DDR Corp (DDR)
DDR Corp.(DDR), incorporated on November 20, 1992, is a self-administered and self-managed real estate investment trust. The Company is engaged in the business of acquiring, owning, developing, redeveloping, expanding, leasing and managing shopping centers. In addition, the Company engages in the origination and acquisition of loans and debt securities, which are generally collateralized directly or indirectly by shopping centers. As of December 31, 2012, the Company�� portfolio consisted of 452 shopping centers , including 206 shopping centers owned through unconsolidated joint ventures and three shopping centers that are otherwise consolidated by the Company in which the Company had an economic interest. These properties consist of shopping centers, lifestyle centers and enclosed malls owned in the United States, Puerto Rico and Brazil. As of December 31, 2012, the Company owned more than 115 million total square feet of gross leasable area (GLA), which includes all of its aforementioned properties. In October 2013, the Company acquired a portfolio of 30 prime power centers from its existing joint venture with Blackstone Real Estate Partners VII L.P. (Blackstone).
The Company owns more than 1,500 acres of undeveloped land, including an interest in land in Canada and Russia. As December 31, 2012, the Company had 14 assets under development and/or redevelopment (consisting of 11 wholly-owned shopping centers and three joint venture shopping centers). As of December 31, 2012, the aggregate occupancy of the Company�� operating shopping center portfolio in which the Company has an economic interest was 91.5%. As of December 31, 2012, the Company had 14 assets under development and/or redevelopment consisting of 11 wholly-owned shopping centers and three joint venture shopping centers.
Advisors' Opinion:- [By Maria Armental and Anna Prior]
American Realty Capital Properties Inc.(ARCP) said it had finalized a deal to sell its multitenant shopping center portfolio for $1.975 billion in cash to a joint venture including a Blackstone affiliate and DDR Corp.(DDR)
- [By Marc Bastow]
Shopping center real estate investment trust DDR Corp. (DDR) raised its quarterly dividend 15% to 15.5 cents per share, payable April 8 to shareholders of record as of March 13.
DDR Stock Dividend Yield: 3.95% - [By Dividend King]
Earnings per share came in at $0.35 while competitors DDR Corp. (DDR) and Kimco Realty Corporation (KIM) reported earnings per share of -$0.56 and $0.27, respectively. With a price to earnings ratio of 123.57, it is clear investors are expecting higher growth from this stock than its competitors, whose price to earnings ratio are twice as half. I think it will not take very long for the stock to appreciate in value at a much higher rate due to higher revenue, good investor and market sentiment towards the stock, and an improved real estate market.
- [By Rich Duprey]
Shopping mall operator DDR� (NYSE: DDR ) announced today its regular second-quarter dividend for three series of preferred shares:
7.375%�Class H stock dividend of�$0.460938�per depositary share. 6.50%�Class J stock dividend of�$0.406250�per depositary share. 6.25%�Class K stock dividend of�$0.41667�per depositary share.The board of directors said the quarterly dividend for all three series of preferreds is payable on July 15 to the holders of record at the close of business on July 1 and�covers the period beginning�April 15�and ending�July 14.
Best Stocks For 2014: Hillenbrand Industries Inc. (HRC)
Hill-Rom Holdings, Inc. manufactures and provides medical technologies and related services for the health care industry worldwide. It offers patient support system, safe mobility and handling solutions, medical equipment rental services, surgical products, and information technology solutions, as well as non-invasive therapeutic products for acute and chronic medical conditions. The company rents and sells patient support systems, which include various bed systems, and integrated and non-integrated therapeutic bed surfaces for use in high, mid, and low acuity settings; and non-invasive therapeutic products and surfaces for the prevention and treatment of various acute and chronic medical conditions, including pulmonary, wound, and bariatric conditions. It also provides rentals and health care provider asset management services for moveable medical equipment, such as ventilators, defibrillators, intravenous pumps, and patient monitoring equipment; mobility solutions, inclu ding lifts and other devices used to move patients; architectural products comprising headwalls and power columns; and health care furniture solutions. In addition, the company develops and markets various communications technologies and software solutions primarily to improve patient safety at the point of care; and surgical products, including a range of positioning devices for use in shoulder, hip, spinal, and lithotomic surgeries, as well as platform-neutral positioning accessories for operating room tables. It sells its products primarily to acute and extended care health care facilities through direct sales force and distributors. The company was formerly known as Hillenbrand Industries, Inc. and changed its name to Hill-Rom Holdings, Inc. in March 2008. Hill-Rom Holdings, Inc. was founded in 1969 and is headquartered in Batesville, Indiana.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Hill-Rom Holdings (NYSE: HRC ) , whose recent revenue and earnings are plotted below. - [By Lisa Levin]
Hill-Rom Holdings (NYSE: HRC) dropped 14.43% to $37.74 after the company reported weaker-than-expected Q1 results and lowered its outlook. The company also announced its restructuring program.
- [By Stephen Simpson, CFA]
On the antennas side, PCTEL antennas can be used in a wide variety of applications from mobile radio to WiFi to GPS and machine-to-machine communication. PCTEL management defines the company's core addressable market as a 5% to 10% slice of a $30 billion market for process automation, smart grid, public safety, fleet management, and enterprise WLAN. Companies ranging from Harris (HRC) to Deere (DE) to Cisco (CSCO) have used PCTEL antennas, and Cisco incorporates the company's antennas into their higher-end wireless products.
Best Stocks For 2014: API Technologies Corp (ATNY)
API Technologies Corp. (API), incorporated on February 2, 1999, designs, develops and manufactures systems, subsystems, radio frequency (RF) and secure communications products, as well as provides electronics manufacturing and engineering services. Its product lines include engineered products (including unmanned aerial vehicles (UAVs), aiming systems and synthesizers), secure communications products (including TEMPEST and emanation security, encryption and secure networking products), subsystems and components (including custom hybrids, terminals, transistors and magnetics), RF and microwave products (including custom filters, amplifiers, connectors and antennas), sensors, and power systems. It operates in two segments: Systems & Subsystems, and Secure Systems & Information Assurance. In June 2013, API sold its Data Bus product line to Data Device Corporation.
The Company offers engineering services (including engineering and design for payloads, ground control systems and commercial product design) and electronics manufacturing services (EMS), such as new product introductions (NPI) and prototypes, turnkey manufacturing and printed circuit board (PCB) assembly. It operates in North America, the United Kingdom, Mexico and China.
Systems & Subsystems
The Systems & Subsystems segment includes the products and services of its operating subsidiaries Spectrum, API Defense Inc., API Defense USA Inc., API Systems Inc., SenDEC, National Hybrid Group, API Electronics, Inc., TM Systems, Keytronics, Filtran Limited and Microwave Technology, Inc. (CMT). Its products and services include RF /microwave solutions, Engineered Systems and Products, Subsystems and Hybrids, Electronics Manufacturing Services, Power Solutions, Sensors and Measurement and Engineering Services. It specializes in the development of custom Integrated Microwave Assemblies (IMAs). It develops and markets engineered systems and products, used for force protection, communication, surveillance and reconnai! ssance. Featured solutions include Unmanned Aerial Vehicles (UAVs) and systems, Unmanned Ground Vehicle (UGV) systems, aiming systems and synthesizers.
The Company�� Custom designed and off-the-shelf subsystems from API support mission critical applications, such as communication equipment, aircraft subsystems systems, computer peripherals, process control equipment, and instrumentation. Featured products include custom hybrids, terminals, transistors and magnetics solutions. It deliver Electronics Manufacturing Services (EMS), including: New Product Introductions (NPI) and prototypes, turnkey manufacturing, Printed Circuit Board (PCB) assembly, electro-mechanical assembly, systems integration, test engineering, turnkey box build and supply chain services. Its power products offer commercial and defense customer�� superior power and energy efficiency. Products span power systems management, distribution, and panels, and custom-designed power supplies for defense and aerospace applications.
The Company offers a range of precision sensors and control products, including position sensing solutions for precision guided munitions, gyros, accelerometers, and inertial measurement sensors for defense and aerospace applications, and position and temperature sensors for industrial and commercial applications. It offers a range of design and engineering services for both defense and commercial customers. Featured areas of expertise include payloads, ground control systems, RF, microwave and millimeterwave.
Secure Systems & Information Assurance
The Secure Systems & Information Assurance segment includes the products and services of its subsidiaries Cryptek, Emcon Emanation Control Inc., Secure Systems and Technologies and the Ion Networks division. API offers customers various secure network and hardware solutions, including Emanation Security, Tempest and secures network access, ruggedized systems and secure networking products. Its products are marketed u! nder the ! Cryptek, ION, Emcon, SST and Netgard brand names. These product offerings are sold to governments and other international organizations that require the level of security in the areas of identity validation, network access management, TEMPEST network intrusion prevention, and secure and encrypted fax, computers and telephones.
The Company�� products and services include Emanation Security and TEMPEST Products, Secure Networking Products, Encryption and Professional Services. The Company�� emanation security products include computing systems, network and communications systems and office systems. Its security appliances and software intelligently enables secure information sharing and systems management across organizations and technologies. Service providers, IT and communications equipment manufacturers, enterprises and government agencies rely on its secure networking products for secure systems for remote management, database guards for secure information sharing and secure virtual enclaves.
The Company�� encryption products and services enable Federal, State and Local governments, Department of Defense agencies, the Department of Homeland Security and the Armed Services to interoperate securely across organizational boundaries and untrusted systems. Its professional services include information assurance and secure networking architecture and design solutions, emanation security testing and engineering and security certification and validation.
The Company competes with Aeroflex, Incorporated, Anaren Inc., Data Devices Inc., Kratos Defense & Security Solutions, Inc., DRS.Finmeccanica, Ducommun Incorporated, Cobham plc, Comtech EF Data Corp. and M/A-COM Technology Solutions Inc.
Advisors' Opinion:- [By Anna Prior]
API Technologies Corp.(ATNY) said it has received a new order to supply high-power amplifier systems as part of a Defense Department maritime requirement. This initial order is part of a multimillion-dollar program with first production delivery set for May 2015, the company said. Shares jumped 6% to $2.81 premarket.
- [By Laura Brodbeck]
Thursday
Earnings Expected From: Lindsay Corporation (NYSE: LNN), Emmis Communications Corporation (NASDAQ: EMMS), API Technologies Corp. (NASDAQ: ATNY) Economic Releases Expected: Australian unemployment rate, Japanese consumer confidence, French industrial output, Italian industrial output, Bank of England interest rate decision, US initial and continuing jobless claimsFriday
Best Stocks For 2014: Federal Resources Investment Group Inc (FED)
Federal Resources Investment Group Inc.( FED) is a Philippines-based holding company engaged. The Company�� primary activities were to invest in, purchase, or otherwise dispose of real and personal property of every kind and description, including shares of stock, bonds, debentures, notes, evidences of indebtedness, and other securities or obligations of any corporation or corporations, association and associations, domestic or foreign. Prior to its change in primary purpose, the Company was previously engaged in the manufacture, marketing and distribution of various adhesives and sealants, contact cement, wood glues, epoxies, coating, and other specialty products, and other chemicals for hardware, construction, do-it-yourself and other applications. The Company�� operating segments include PVC Resins and Sealants, Coatings and adhesives. The Company is still in the process of winding up its manufacturing and trading operations and selling its remaining inventories. Advisors' Opinion:- [By Canadian Value]
Nearly all emerging markets took a hit this summer amid speculation the US Federal Reserve Bank (Fed) would soon begin ��apering��its prolonged asset purchase plan, which had pumped large amounts of liquidity into the markets globally. When you hear about this ��apering��of the Fed�� $85 billion monthly bond purchases, it�� important to understand the facts. Tapering isn�� the same as tightening. The Fed-fueled liquidity already pumped in is still working through the system. Additionally, Japan and other global central banks are printing money, adding to the pot.
- [By Canadian Value]
In the US, we believe the key is whether the economic recovery will be self-sustaining in the absence of the excessively easy monetary policy that the US Federal Reserve (Fed) has been providing via its longstanding Treasury asset purchase program known as Quantitative Easing (QE). Can the Fed orchestrate a steady, manageable rise in interest rates? Will employment and wage growth gather strength and create a virtuous growth cycle without Fed support? And will corporate earnings continue to come through as anticipated by the steady expansion we have seen in valuation multiples? These are all unknowns, but will likely be important parts of the equation for the US market.
Best Stocks For 2014: Arca Biopharma Inc.(ABIO)
ARCA biopharma, Inc., a biopharmaceutical company, engages in the development of genetically-targeted therapies for cardiovascular diseases. Its principal product candidate, Gencaro (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure and also for the prevention of atrial fibrillation in patients with heart failure. The company has identified common genetic variations in the cardiovascular system that it believes interact with Gencaro?s pharmacology and may predict patient response. ARCA has collaboration with Laboratory Corporation of America to develop the Gencaro Test, a companion test for the genetic markers that identify these common genetic variations. The company is headquartered in Broomfield, Colorado.
Advisors' Opinion:- [By Roberto Pedone]
One biopharmaceuticals player that's starting to trend within range of triggering a major breakout trade is Arca Biopharma (ABIO), which is developing genetically-targeted therapies for cardiovascular diseases. This stock has been under pressure by the sellers so far in 2013, with shares down big by 37%.
If you take a look at the chart for Arca Biopharma, you'll notice that this stock has been trending sideways and consolidating for the last two months and change, with shares moving between $1.29 on the downside and $1.53 on the upside. Shares of ABIO are now starting to uptrend over the last month as the stock moves within range of triggering a major breakout trade above the upper-end of its recent sideways trading chart pattern.
Traders should now look for long-biased trades in ABIO if it manages to break out above some near-term overhead resistance levels at $1.47 to $1.53 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 331,253 shares. If that breakout triggers soon, then ABIO will set up to re-test or possibly take out its next major overhead resistance level at $1.65 a share. Any high-volume move above $1.65 will then give ABIO a chance to re-fill some of its previous gap down zone from May that started near $2.80 a share.
Traders can look to buy ABIO off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $1.38 a share, or near more support at $1.29 a share. One can also buy ABIO off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Antè´¸nio Costa] Arca Biopharma Inc (NASDAQ: ABIO) OBV Indicator continues its uptrend showing investor interest. A restest of 1.8 seems very likely. Last week, Dawson James initiated coverage on shares with a buy rating and a $3.75 target price.
During the day I tweet many times to my readers. I encourage everybody to subscribe AC Investor Blog twitter and newsletter, so you can receive my trade ideas and stock news in real time.
- [By Bryan Murphy]
Three days ago I suggested Arca Biopharma Inc. (NASDAQ:ABIO) was a buy, recommending anyone who was lucky enough to own GW Pharmaceuticals PLC (NASDAQ:GWPH) at the time take their profits on GWPH and place that money in Arca. After several weeks' worth of buildup, and after finally seeing a decided break above the horizontal ceiling at $1.50, ABIO looked like it had rocked its way out of a rut and was headed for sunnier skies and greener pastures.
Best Stocks For 2014: bluebird bio Inc (BLUE)
bluebird bio, Inc., incorporated on April 16, 1992, is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy. Gene therapy seeks to introduce a functional copy of the defective gene into a patient�� own cells, a process called gene transfer. Through gene transfer, a functional copy of the mutated gene is delivered to the patient�� cells, thereby correcting the underlying genetic defect that causes aberrant gene expression. As of December 31, 2012, the Company is conducting a Phase I/II clinical study in France evaluating an earlier generation of its LentiGlobin vector for the treatment of �-thalassemia major and SCD. Initial proof-of-concept data from this study were published in Nature. During the year ended December 31, 2013, the Company plans to initiate an extension of this study under a revised protocol for LentiGlobin, which the Company refers to as the HGB-205 Study. The Company also plans o initiate a second Phase I/II clinical program in the United States for LentiGlobin, which the Company refers to as the HGB-204 Study, for �-thalassemia major. In March 2013, the Company entered into a strategic collaboration with Celgene Corporation, or Celgene, to discover, develop and commercialize, disease-altering gene therapies in oncology.
Its gene therapy platform is based on viral vectors that utilize a modified, non-replicating version of the Human Immunodeficiency Virus Type 1 (HIV-1) virus, that has been stripped of all of the components required for it to self-replicate and infect additional cells. The HIV-1 virus is part of the lentivirus family of viruses, as a result of which the Company refer to its vectors as lentiviral vectors. Its lentiviral vectors are used to introduce a functional copy of a gene to the patient�� own isolated blood stem cells, called hematopoietic stem cells (HSCs), which reside in a patient�� bone marrow and are capable of differentiating int! o a wide range of cell types. HSCs are dividing cells, thus its approach allows for sustained expression of the modified gene as the Company is able to take advantage of a lifetime of replication of the gene-modified HSCs. Additionally, the Company has developed a cell-based vector manufacturing process that is both reproducible and scalable.
Adrenoleukodystrophy
Adrenoleukodystrophy is a rare X-linked, inherited, neurological disorder that is often fatal. ALD is caused by mutations in the ABCD1 gene which encodes for a protein called the ALD protein (ALDP), which plays a critical role in the breakdown and metabolism of long-chain fatty acids (VLCFA). Without functional ALDP, VLCFA accumulate in cells including neural cells in which they cause damage to the myelin sheath, a protective and insulating membrane that surrounds nerve cells in the brain. This damage can result in decreased motor coordination and function, visual and hearing disturbances, the loss of cognitive function, dementia, seizures, adrenal dysfunction and other complications, including death. ALD is divided into various sub-segments with three main phenotypes that impact brain function: CCALD (Childhood cerebral adrenoleukodystrophy, AMN (Adrenomyeloneuropathy) and ACALD (Adult Cerebral ALD).
�-thalassemia
�-thalassemia is a rare hereditary blood disorder caused by a genetic abnormality of the �-globin gene resulting in defective red blood cells (RBCs). Genetic mutations cause the absence or reduced production of the beta chains of hemoglobin, or �-globin, thereby preventing the proper formation of hemoglobin A, which normally accounts for greater than 95% of the hemoglobin in the blood of adults. Hemoglobin is an iron-containing protein in the blood that carries oxygen from the respiratory organs to the rest of the body. Hemoglobin A consists of four chains-two chains each of a-globin and �-globin. Normally existing at an approximate 1:1 ratio, genetic mutations that impair t! he produc! tion of �-globin can lead to a relative excess of a-globin, premature death of red blood cells. The clinical implications of the a-globin/�-globin imbalance are two-fold: first, patients lack sufficient RBCs and hemoglobin to effectively transport oxygen throughout the body and can become severely anemic; and second, the shortened life span and ineffective production of RBCs can lead to other complications such as splenomegaly, marrow expansion, bone deformities, and iron overload in organs.
Sickle cell disease
Sickle cell disease (SCD) is a hereditary blood disorder resulting from a mutation in the �-globin gene that causes polymerization of hemoglobin proteins and abnormal red blood cell function. The disease is characterized by anemia, vaso-occlusive pain crisis (a common complication of SCD in which there is severe pain due to obstructed blood flow in the bones, joints, lungs, liver, spleen, kidney, eye, or central nervous system), infections, stroke, overall poor life and early death in a subset of patients. Under low-oxygen conditions, which are exacerbated by the red blood cell abnormalities, the mutant hemoglobin aggregates causing the RBCs to take on a sickle shape (sickle cells), which causes them to aggregate and obstruct small blood vessels, thereby restricting blood flow to organs resulting in pain, cell death and organ damage. If oxygen levels are restored, the hemoglobin can disaggregate and the RBCs return to their normal shape, but over time, the sickling damages the cell membrane and the cells fail to return to the normal shape even in high-oxygen conditions.
Advisors' Opinion:- [By Garrett Cook]
Bluebird Bio (NASDAQ: BLUE) shares shot up 33.61 percent to $34.86 following the presentation of positive data on LentiGlobin BB305 at the European Hematology Association (EHA).
No comments:
Post a Comment